XFOR - NASDAQ
X4 Pharmaceuticals, Inc.
$4.01
-0.74%X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
At a Glance
Live SnapshotX4 Pharmaceuticals, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
X4 Pharmaceuticals, Inc. Income Statement
XFOR • NASDAQ
| X4 Pharmaceuticals, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||||
35.1M | 2.6M | 0.0 | 0.0 | 0.0 | 3M | 0.0 | 3.5M | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | |||||||||||
(6.3M) | (797K) | (0.0) | (0.0) | (1.9M) | (0.0) | (672K) | (103K) | (195K) | (300K) | (400K) | |
28.9M | 1.8M | 0.0 | 0.0 | -1.9M | 3M | -672K | 3.4M | -195K | -300K | -400K | |
OPERATING INCOME | |||||||||||
(116.2M) | (38.2M) | (107.5M) | (87.6M) | (73.5M) | (62.9M) | (47.8M) | (46.2M) | (32.3M) | (22M) | (12.7M) | |
(43.5M) | (61.5M) | (35.5M) | (27M) | (24.7M) | (20.9M) | (17.6M) | (18.4M) | (8M) | (6.5M) | (2.1M) | |
(72.7M) | (81.6M) | (72M) | (61.1M) | (48.8M) | (41.9M) | (30.2M) | (31M) | (28.1M) | (17.8M) | (12.7M) | |
-86.9M | -36.4M | -107.5M | -87.6M | -75.3M | -59.9M | -51.7M | -45.9M | -36.1M | -24.3M | -14.8M | |
PRE-TAX INCOME | |||||||||||
(8.9M) | (8.8M) | (5.8M) | (4M) | (3.6M) | (2.7M) | (2.1M) | (1M) | (2.1M) | (2.5M) | (472K) | |
-4.3M | -3M | -1.2M | -3.8M | -3.6M | -2.4M | -950K | -230K | -1.9M | 0.0 | 0.0 | |
(0.0) | -105M | (0.0) | -509K | (0.0) | (0.0) | (0.0) | -85K | -16K | (104K) | -77K | |
7.7M | -739K | 6.4M | -6.3M | -13.3M | -2.1M | -1.1M | 2.9M | 2.3M | 6.5M | 1.6M | |
-79.2M | -37.1M | -101.1M | -93.8M | -88.7M | -62M | -52.8M | -43M | -33.9M | -23M | -13.2M | |
NET INCOME | |||||||||||
(41K) | (310K) | (78K) | (28K) | (17K) | (148K) | (0.0) | (3.9M) | (0.0) | (2.6M) | (0.0) | |
-79.2M | -37.5M | -101.2M | -93.9M | -88.7M | -62.1M | -56.6M | -43M | -33.9M | -23M | -13.2M |
SEC Filings
XFOR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K/A 8-K/A 2026 (Amended) N/A | May 13, 2026 | May 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 11, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
S-3 S-3 N/A | May 06, 2026 | May 06, 2026 | ||
DEF 14A DEF 14A 2026 N/A | March 20, 2026 | March 20, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 17, 2026 | December 31, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 05, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 05, 2025 | November 05, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 27, 2025 | October 23, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 17, 2025 | September 15, 2025 | 2025 |
Related Guides
Continue your XFOR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.